Literature DB >> 2149875

Antinociceptive effect of intrathecally-administered desipramine and zimelidine in rats.

A Lund1, A Tjølsen, K Hole.   

Abstract

The effect of intrathecally (i.th.) administered desipramine and zimelidine, in doses of 5, 10 and 50 micrograms, were investigated in the tail-flick test with simultaneous measurement of the temperature of the tail skin and in the increasing temperature hot-plate test. A constant negative correlation between the temperature of the tail skin and tail-flick latency, as described previously, was found. For all doses tested, desipramine induced longer tail-flick latencies, 10 min after injection than vehicle and the temperature of the tail skin tended to increase less in this group than in controls. After adjustment of the tail-flick latencies for the changes in the temperature of the tail skin, an antinociceptive effect of desipramine was still found. For zimelidine, only the largest dose (50 micrograms) was found to be antinociceptive, after adjustment for the tail skin temperature. In the increasing temperature hot-plate test, no antinociceptive effect of these antidepressants was found. For desipramine and zimelidine, the effect in the tail-flick test, 10 min after injection, indicates that the antinociceptive effect of these drugs may have, at least partly, a spinal site of action. In the increasing temperature hot-plate test, the response is integrated supraspinally. This may partly explain the lack of effect in this test when desipramine and zimelidine were administered intrathecally.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2149875     DOI: 10.1016/0028-3908(90)90155-k

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  1 in total

1.  Electroacupuncture at 2/100 hz activates antinociceptive spinal mechanisms different from those activated by electroacupuncture at 2 and 100 hz in responder rats.

Authors:  Josie Resende Torres da Silva; Marcelo Lourenço da Silva; Wiliam Alves Prado
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-16       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.